This is a registry record, not a result. A trial being listed, recruiting or completed says nothing by itself about whether the compound works or is safe.
| Registry number | NCT07670416 |
|---|---|
| Status | Recruiting |
| Phase | Phase 3 |
| Sponsor | Hoffmann-La Roche |
| Enrollment | 300 participants |
| Design | Interventional, Randomized, Parallel, Masking: Double |
| Conditions | Obesity; Overweight; Type 2 Diabetes Mellitus (T2DM) |
| Interventions | Enicepatide; Placebo |
| Start | Jul 3, 2026 |
| Primary completion | Feb 24, 2028 |
| Study completion | Mar 15, 2028 |
| Results posted | Not yet |
| Registry last updated | Sep 10, 2026 |
Compounds on this site that cite this trial
What the registry says the trial is about
The purpose of this study is to assess the efficacy and safety of enicepatide, a dual glucagon-like peptide-1 (GLP-1)/glucose-dependent insulinotropic polypeptide (GIP) receptor agonist (RA) being developed for chronic weight management, as an adjunct to a reduced-calorie diet and increased physical activity in participants without Type 2 diabetes mellitus (T2DM) who have obesity or overweight with at least one weight-related comorbidity, and in participants with T2DM who have obesity or overweight.
Primary outcomes
These are what the trial was designed to measure first. They are registered in advance, which is what makes a later result checkable.
| Outcome measure | Time frame |
|---|---|
| Percent Change From Baseline in Body Weight at Week 52 | Baseline through Week 52 |
39 secondary outcomes also registered. See the registry record for the full list.
Source: ClinicalTrials.gov (U.S. National Library of Medicine). Last checked against the registry on Oct 3, 2026. See the trial changes feed for what has changed recently.
